Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.TROV · Entity 6917 | Director | June 08, 2018 | June 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date June 08, 2018 · Filed June 14, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,839 |
Reported balance
After 2018-06-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-06-08 · Purchase · Acquired 10,000 · Balance 28,839 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2018 Filed Jun 11, 2018 10:03 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0000899243-18-015835 · doc4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,061 Read SEC document |
| June 08, 2018 Filed Jun 14, 2018 00:45 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0000899243-18-016468 · doc4a.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,839 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001898 · doc4.xml · derivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,586 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000532 · doc4a.xml · derivative · entry 2 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000532 · doc4a.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000487 · doc4.xml · derivative · entry 2 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000487 · doc4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:21 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061156 · a4.xml · derivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,264 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:02 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | SaleCommon Stock | 8,334 | $0.69 | $5,750.46 |
DisclosureSEC source: 0001104659-17-055831 · a4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,394 Read SEC document |
| September 02, 2017 Filed Sep 7, 2017 00:55 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 8,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055900 · a4.xml · derivative · entry 2 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 8,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 8,484 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 8,484 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. Read SEC document |
| September 02, 2017 Filed Sep 7, 2017 00:55 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 8,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055900 · a4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 8,484 restricted stock units, all of which vested on September 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 22:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000636 · a4.xml · derivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSUs shall vest on January 2, 2018. F2 · derivative.expiration_date: The RSUs shall vest on January 2, 2018. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 21:56 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 8,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000961 · a4a.xml · derivative · entry 2 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,151 Underlying: Common Stock · 8,484 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest on September 2, 2017. F3 · derivative.expiration_date: The RSUs shall vest on September 2, 2017. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 21:56 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000961 · a4a.xml · derivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSUs shall vest on January 2, 2018. F2 · derivative.expiration_date: The RSUs shall vest on January 2, 2018. Read SEC document |
| December 19, 2016 Filed Dec 19, 2016 21:51 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 10,000 | $2.10 | $21,000.00 |
DisclosureSEC source: 0001104659-16-162837 · a4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,728 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 11:04 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 14,966 | $2.00 | $29,932.00 |
DisclosureSEC source: 0001104659-16-162687 · a4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,728 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.